# CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

> **NCT04369664** · PHASE4 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 151 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Statin
- **DRUG:** PCSK9 inhibitor
- **DRUG:** Ezetimibe 10mg

## Key facts

- **NCT ID:** NCT04369664
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-10-19
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04369664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04369664, "CHOlesterol Lowering and Residual Risk in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04369664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*